A pragmatic approach to biochemical systems theory applied to an α-synuclein-based model of Parkinson's disease

This paper presents a detailed systems model of Parkinson's disease (PD), developed utilizing a pragmatic application of biochemical systems theory (BST) intended to assist experimentalists in the study of system behavior. This approach utilizes relative values as a reasonable initial estimate for BST and provides a theoretical means of applying numerical solutions to qualitative and semi-quantitative understandings of cellular pathways and mechanisms. The approach allows for the simulation of human disease through its ability to organize and integrate existing information about metabolic pathways without having a full quantitative description of those pathways, so that hypotheses about individual processes may be tested in a systems environment. Incorporating this method, the PD model describes alpha-synuclein aggregation as mediated by dopamine metabolism, the ubiquitin-proteasome system, and lysosomal degradation, allowing for the examination of dynamic pathway interactions and the evaluation of possible toxic mechanisms in the aggregation process. Four system perturbations: elevated alpha-synuclein aggregation, impaired dopamine packaging, increased neurotoxins, and alpha-synuclein overexpression, were analyzed for correlation to qualitative PD system hypotheses present in the literature, with the model demonstrating a high level of agreement with these hypotheses. Additionally, various PD treatment methods, including levadopa and monoamine oxidase inhibition (MAOI) therapy, were applied to the disease models to examine their effects on the system. Future additions and refinements to the model may further the understanding of the emergent behaviors of the disease, helping in the identification of system sensitivities and possible therapeutic targets.

[1]  P. Molinoff,et al.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .

[2]  J. Luzio,et al.  Ubiquitin-dependent sorting of integral membrane proteins for degradation in lysosomes. , 2007, Current opinion in cell biology.

[3]  H. Fedorow Neuromelanin in human dopamine neurons. , 2005 .

[4]  E. Bennett,et al.  Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.

[5]  A. Cuervo,et al.  Chaperone-mediated autophagy in aging and neurodegeneration: Lessons from α-synuclein , 2007, Experimental Gerontology.

[6]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[7]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[8]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[9]  L. Petrucelli,et al.  Co-association of parkin and α-synuclein , 2001 .

[10]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[11]  L. Hicke Ubiquitin‐dependent internalization and down‐regulation of plasma membrane proteins , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of α-synuclein , 2008, Experimental Neurology.

[13]  D. Ecker,et al.  A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. , 1989, Science.

[14]  P. Riederer,et al.  Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. , 2008, Parkinsonism & related disorders.

[15]  C. Olanow,et al.  Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.

[16]  D. Sulzer,et al.  α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.

[17]  D. Fell Metabolic control analysis: a survey of its theoretical and experimental development. , 1992, The Biochemical journal.

[18]  P. Højrup,et al.  Proteasomal Inhibition by α-Synuclein Filaments and Oligomers* , 2004, Journal of Biological Chemistry.

[19]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[20]  M. Savageau Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. , 1969, Journal of theoretical biology.

[21]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[22]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[23]  M. Savageau Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. , 1969, Journal of theoretical biology.

[24]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[25]  Poorvi Kaushik,et al.  Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis , 2007, Journal of Computational Neuroscience.

[26]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[27]  M. Hallett,et al.  Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[28]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[29]  S. Schreiber,et al.  Downregulation of free ubiquitin: a novel mechanism of p53 stabilization and neuronal cell death. , 2001, Brain research. Molecular brain research.

[30]  D. Rubinsztein Autophagy Induction Rescues Toxicity Mediated by Proteasome Inhibition , 2007, Neuron.

[31]  Shosuke Ito,et al.  A Chemist's View of Melanogenesis , 2003 .

[32]  Graeme Eisenhofer,et al.  Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine , 2004, Pharmacological Reviews.

[33]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[34]  J. Bolton,et al.  Role of quinones in toxicology. , 2000, Chemical research in toxicology.

[35]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[36]  H. Ischiropoulos,et al.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association? , 2003, The Journal of clinical investigation.

[37]  T. Dawson,et al.  Parkin-associated Parkinson’s disease , 2004, Cell and Tissue Research.

[38]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[39]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[40]  D. Sulzer,et al.  Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease , 2007, Trends in Neurosciences.

[41]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[42]  Barry Halliwell,et al.  Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.

[43]  P Mendes,et al.  Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. , 1997, Trends in biochemical sciences.

[44]  M. Farrer,et al.  Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .

[45]  Juan Carlos Nuño,et al.  METATOOL: for studying metabolic networks , 1999, Bioinform..

[46]  K. O’Malley,et al.  The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.

[47]  K D Wilkinson,et al.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. , 1989, Science.

[48]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[49]  F. Gorin,et al.  Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson’s disease , 2006, Neuroscience.

[50]  Daewoo Lee,et al.  Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein. , 2007, The European journal of neuroscience.

[51]  N. Hattori,et al.  Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin‐like domain , 2003, EMBO reports.

[52]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[53]  Stefan Schuster,et al.  YANA – a software tool for analyzing flux modes, gene-expression and enzyme activities , 2005, BMC Bioinformatics.

[54]  A. Cuervo,et al.  Oxidative stress and autophagy. , 2006, Antioxidants & redox signaling.

[55]  S. Emr,et al.  Receptor downregulation and multivesicular-body sorting , 2002, Nature Reviews Molecular Cell Biology.

[56]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[57]  P. Blumbergs,et al.  Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. , 1995, Brain : a journal of neurology.

[58]  B. Sommer,et al.  Part I: Parkin-associated proteins and Parkinson’s disease , 2003, Neuropharmacology.

[59]  P. Højrup,et al.  Proteasomal inhibition by alpha-synuclein filaments and oligomers. , 2004, The Journal of biological chemistry.

[60]  J. Keller,et al.  Dopamine induces proteasome inhibition in neural PC12 cell line. , 2000, Free radical biology & medicine.

[61]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[62]  N. Heintz,et al.  Autophagy and Its Possible Roles in Nervous System Diseases, Damage and Repair , 2005, Autophagy.

[63]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[64]  T. Nagatsu [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.

[65]  V. Buchman,et al.  Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.

[66]  Vidya N. Nukala,et al.  Characterization of chronic low‐level proteasome inhibition on neural homeostasis , 2003, Journal of neurochemistry.

[67]  M. Zigmond,et al.  A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  Eberhard O. Voit,et al.  Computational Systems Analysis of Dopamine Metabolism , 2008, PloS one.

[69]  Y. Imai,et al.  Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.

[70]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[71]  L. Pallanck,et al.  Parkin A Multipurpose Neuroprotective Agent? , 2003, Neuron.

[72]  Mudita Singhal,et al.  COPASI - a COmplex PAthway SImulator , 2006, Bioinform..

[73]  D. Sulzer,et al.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.

[74]  I. Sora,et al.  The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Eberhard O. Voit,et al.  Computational Analysis of Biochemical Systems: A Practical Guide for Biochemists and Molecular Biologists , 2000 .

[77]  Linda Hicke,et al.  Ubiquitin and proteasomes: Protein regulation by monoubiquitin , 2001, Nature Reviews Molecular Cell Biology.

[78]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[79]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[80]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[81]  Martin Rechsteiner,et al.  Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.

[82]  K. Vrana,et al.  Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.

[83]  D. Gray,et al.  Damage control – a possible non‐proteolytic role for ubiquitin in limiting neurodegeneration , 2001, Neuropathology and applied neurobiology.

[84]  B. Bergamasco,et al.  Modifications of the iron–neuromelanin system in Parkinson's disease , 2006, Journal of neurochemistry.

[85]  Mark R Cookson,et al.  The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.

[86]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[87]  A. Ciechanover,et al.  The ubiquitin system. , 1998, Annual review of biochemistry.

[88]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[89]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[90]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[91]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[92]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[93]  MoonHee Lee,et al.  Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .

[94]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[95]  J. Dice,et al.  Mechanisms of chaperone-mediated autophagy. , 2004, The international journal of biochemistry & cell biology.

[96]  Li Chen,et al.  α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains* , 2005, Journal of Biological Chemistry.

[97]  M. Savageau Biochemical systems analysis. III. Dynamic solutions using a power-law approximation , 1970 .